Nemaura Pharma today announced it has entered in to a partnership with a global Pharmaceutical company to advance one of its microneedle based Pharmaceutical Product, for global markets. As part of the agreement the partner company will fund all development activities to establish clinical proof of concept, and subsequently will have first rights of refusal for a global license. The product applies to the burgeoning global pain market and provides a novel method of treatment using a well established drug molecule. This partnership exemplifies the specialism and strength of the technical team that Nemaura has built and continues to build as it advances more complex drug products towards registration and commercialisation.
Menu